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 2. Abbreviations 
ACS   Acute coronary syndromes 
apo    Apolipoprotein  
APRIL   A proliferation inducing ligand 
CAD    Coronary artery disease 
CD40L  CD40 ligand 
CRP   C reactive protein 
CSF    Colony stimulating factor 
HDL   High density lipoprotein 
HVEM  Herpes virus entry mediator 
IFN   Interferon 
IL   Interleukin  
LDL   Low density lipoprotein 
LIGHT Lymphotoxin-like, exhibits inducible expression, and competes 
with HSV glycoprotein D (gD) for HVEM, a receptor expressed by 
T lymphocytes 
LPS   Lipopolysaccharide  
MCP   Monocyte chemoattractant peptide  
MAPK   Mitogen activated protein kinase 
MI    Mycardial infarction 
MMP   Matrix metalloproteinase 
NFB   Nuclear factor-B 
NYHA   New York heart association 
OPG   Osteoprotegerin  
oxLDL  oxidized LDL 
PCR   Polymerase chain reaction 
PAR   Proteinase activated receptor 
PCI    Percutaneous coronary intervention 
RANKL  Receptor activator of NFB ligand 
ROS    Reactive oxygen species 
SAP   Stable angina pectoris 
SR-A    Scavenger receptor-A 
SMC    Smooth muscle cells 
STEMI   ST-segment elevation MI 
TNF   Tumor necrosis factor  
TNFRSF  TNF receptor superfamily 
UAP   Unstable angina pectoris 
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 4. Introduction 
4.1 General background 
Atherosclerotic disorders are the underlying cause of most cases of myocardial infarction, 
stroke and gangrene, are the most common lethal disease in Western societies and are 
expected to be the number one killer globally in 2020.1 Despite better understanding of 
the pathobiology, knowledge of risk factors and improved treatment strategies, CAD and 
other atherosclerotic disorders, still remains a progressive disease with high morbidity. 
4.1.1 Epidemiology and risk factors 
Back only to the mid-nineties, optimistic views held that CAD would be eliminated by 
the end of the 20th century due to treatment of hypercholesterolemia and hypertension. 
But rapidly increasing prevalence in developing countries2 and eastern Europe as well as 
rising incidence of obesity and diabetes in the western world have defied this prediction 
and challenge us to consider new strategies for prediction, prevention and treatment.3 
Currently, cardiovascular disease cause 38 percent of all deaths in North America and are 
the most common cause of death in European men under 65.4 
About one of four deaths in Norway is caused by CAD. The incidence is higher in 
men, and rises with age in both sexes. Above the age of 60 the difference between sexes 
declines, but never disappears. Incidence of symptomatic CAD in Norway is described in 
the population-based “Tromsø-study” which included 27,000 persons above 25 years. 
Here, 4.1% of the men and 1.6% of the women reported that they had had a myocardial 
infarction (MI). Further, 2.6% of the participants reported that they were suffering from 
angina pectoris.    
The most established risk factor of CAD is hypercholesterolemia (elevated low-
density lipoprotein [LDL] cholesterol).5 However, atherosclerotic progression vary 
considerably at any given plasma cholesterol level, suggesting that other risk factors may 
be involved.6 Other risk factors, predisposing factors and factors that are associated with 
cardiovascular risk are presented in Table 1.  
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Table 1. Proven and putative risk factors of cardiovascular diseases#
 
Risk factors that are casually linked: 
1. Tobacco consumption 
2. Elevated LDL 
3. Low HDL 
4. High blood pressure 
5. Elevated glucose 
6. Physical inactivity* 
7. Obesity* 
8. Diet* 
Risk factors that show associations: 
1. Elevated prothrombotic factors 
2. Markers of infection and inflammation 
3. Elevated homocysteine 
4. Elevated lipoprotein (A) 
5. Low socioeconomic status* 
6. Psychological factors and breakdown of social structures*  
*Predisposing risk factors: A predisposing risk factor is presumed to work, at least partly, 
through an impact on other risk factors that act directly. It is likely that some of the 
predisposing factors also have direct effects. 
#Modified from Yusuf5 
 
4.1.2 Clinical features of atherosclerosis 
The clinical manifestations of CAD roughly divide in two entities: chronic ischemic 
CAD, which often manifests as stable angina but may also be asymptomatic, and acute 
coronary syndromes (ACS), which include unstable angina pectoris (UAP), myocardial 
infarction (MI) and sudden cardiac death. Atherosclerotic coronary artery disease 
manifests in the arteries as an asymmetric focal thickening of the intima by accumulation 
of lipid droplets and immune cells, typically evolving into a stenotic lesion that encroach 
luminal space and restrict blood flow. Thus, particularly under situations of increased 
cardiac demand, ischemia occurs, leading to symptoms of stable angina pectoris.7,8 These 
are typically chest pain and/or dyspnea induced by physical exertion or psychological 
stress. Grading of the symptoms of angina pectoris may be done according to consensus 
systems such as the New York Heart Association (NYHA) classification and the 
Canadian Cardiovascular Society classification which both classify severity from I to IV.9 
The diagnosis of stable angina is based on typical clinical history, exercise 
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electrocardiography (ECG), nuclear techniques for evaluation of myocardial perfusion, 
and often coronary angiography revealing significant stenosis in the coronary vessels. In 
contrast to the progressive stenosis of stable angina, unstable angina and acute 
myocardial infarction seem to be caused by a sudden physical disruption of the 
atherosclerotic plaque, triggering subsequent thrombus formation and vascular 
obstruction. Unstable angina is clinically defined as chest pain at rest within the past 48 
hours; a classification is presented by Braunwald.10,11  The diagnostic criteria is based on 
biochemical markers of myocardial injury, particularly the cardiac troponins I and T but 
also creatine kinase (CK)-MB mass. The patient further may present with or without 
electrocardiographic changes, i.e., transient ST-segment depression or T-wave inversion, 
and with or without elevated myocardial markers as troponin T or troponin I. The 
presence or absence of these characteristics (ECG changes and/or elevated troponins or 
no changes) put the patient into a high-risk or low-risk state for developing acute MI or 
death within 30 days.11  
In 2000, The Joint European Society of Cardiology/American College of 
Cardiology (ESC/ACC) Committee for the redefinition of myocardial infarction12 
suggested that any amount of necrosis resulting from ischemia should be diagnosed as a 
MI. As a consequence of this new definition, patients who would previously have been 
considered to have unstable angina are being diagnosed with a MI. Accordingly, patients 
with MI are divided into ST-segment elevation MI (STEMI) and non-STEMI. In a recent 
study, STEMI patients were more likely to receive fibrinolysis or undergo percutaneous 
coronary intervention (PCI), but less likely to have bypass surgery. At discharge, patients 
with STEMI received more aggressive secondary prevention therapies than those with 
NSTEMI, which was not supported by differences in disease severity. 
   
4.1.3 Current treatment strategies 
Treatment of cardiovascular disease has improved during the last 20 years, both with 
respect to revascularization with bypass grafting or PCI, and evidence-based medical 
therapy, which in principle rests on three cornerstones: anti-platelet, anti-coagulant, and 
fibrinolytic therapy; vaso-relaxing treatment by beta adrenergic (-) blockers and nitrates; 
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and cholesterol-lowering therapy. Anti-platelet therapy is the basic treatment strategy, 
and aspirin is currently the most used drug, reducing the risk of death and MI in both 
stable and unstable angina.13-16 The thienopyridines ticlodipine and clopidogrel and 
intravenous glycoprotein IIb/IIIa inhibitors may be well as effective in preventing 
coronary events as aspirin, recommended if aspirin-intolerance and as a bridge to and 
after acute PCI, respectively.17, 18 Moreover, the coagulation inhibitor heparin adds to the 
anti-coagulation treatment strategy of unstable angina.19 Thrombolytic or fibrinolytic 
therapy is also frequently used, in particular where facilities for PCI are not available. -
blockers give symptomatic relief in both stable and unstable angina, and risk reduction is 
evident in patients with previous MI or reduced left ventricular function. However, data 
from randomized trials supporting risk reduction in angina are more limited.20 Nitrates 
and selected calcium antagonists are well-established as symptom relievers, but have no 
risk-reducing effects. Finally, cholesterol-lowering therapy with statins is highly effective 
in reducing the risk of major events in all groups of CAD, both chronic and acute.21-26 
However, despite state-of-the art treatment, CAD is a progressive disease with high 
morbidity and mortality, suggesting that pathogen mechanisms remain active and 
unmodified by current treatment modalities. In our opinion, persistent immune activation 
may represent such mechanism.  
4.1.4 The atherosclerotic process  
The normal intimal layer of an artery is covered on the luminal surface of a monolayer of 
endothelial cells that is critical for vascular homeostasis. Below intima is the media layer, 
containing mainly smooth muscle cells (SMCs), and finally the outer adventitia layer, 
containing connective tissue, collagen and elastic fibers. Several mechanisms have been 
proposed to explain the initiating events in atherosclerosis, and three main hypotheses 
have emerged; the response-to-injury, the response-to-retention and the oxidative 
modification hypothesis.27-29 These hypotheses are now considered to present the main 
contributory factors in initiation of atherosclerosis, not mutually exclusive but compatible 
with each other, explaining how endothelial cells become activated by risk factors such as 
hypercholesterolemia, tobacco smoking, inflammation and disturbed hemodynamic flow. 
The activated endothelium has increased permeability and invasion of T cells and 
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monocytes as well as accumulation of lipoproteins in the intima are hallmark 
characteristics of atherosclerosis.30 Here, according to the oxidation hypothesis, LDL 
cholesterol is tightly adhered to proteoglycans, undergoing progressive oxidation in the 
microenvironment which is relatively sequestered from the plasma antioxidants.6 
Simultaneously, intimal monocytes proliferate and differentiate to macrophages which 
perform rapid uptake of oxidized LDL (oxLDL) particles, subsequently transforming the 
cells into lipid-laden macrophages or so called foam-cells. These are the dominant cell 
type in the early atherosclerotic plaque, or “fatty streak”, which is prevalent in younger 
individuals and cause no symptoms. This nascent lesion can either disappear with time or 
evolve to stenotic atheromas. Further plaque progression consists of recruitment and 
mitosis of leukocytes as well as migration and proliferation of vascular SMC and 
continued accumulation of LDL, creating the fibro-fatty plaque typically characterized as 
a foam-cell-surrounded, lipid-rich, necrotic core, surrounded by a cap of SMC and 
collagen-rich matrix.31 The plaque may be “silent” or lead to ischemia with symptoms of 
stable angina pectoris. However, ACS, i.e., unstable angina and acute MI, seem to be 
caused by plaque disruption, rather than complete stenosis; rupture of the fibrous cap  
promote thrombus formation that either may lead to partly or totally occlusion of the 
vessel lumen and acute disease. Resorption of thrombi often causes healing responses 
that cause the fibro-fatty plaque to evolve into a fibrous and often calcified plaque with 
significant stenosis. 30 
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Figure 1. Atherogenesis – interaction between lipids and inflammation 
The atherosclerotic process in the artery wall is initiated by interaction of endothelial dysfunction (panel A) 
and retention, oxidative modification and scavenging of LDL in the intima (panel B). Endothelial 
dysfunction is characterized by increased endothelial permeability and increased expression of adhesion 
molecules, chemotactic proteins and growth factors causing adhesion, rolling and migration of monocytes 
and T-cells into the intima. After entering the intima, monocytes differentiate into macrophages that release 
reactive oxygen species (ROS) and several cytokines leading to enhanced expression of adhesion molecules 
and subsequent monocyte migration. This promotes the pro-inflammatory cascade with activation of T cells 
secreting mainly Th-1 cytokines, activating macrophages and other intima cells leading to inflammation. 
Endothelial dysfunction also leads to increased passive transport of LDL into the subendothelial space, 
where it interact with and is retained by proteoglycans. At limiting levels of antioxidants, the lipids and 
proteins of LDL undergoes oxidative modifications as a result interaction with ROS and enzymes, forming 
oxidized LDL (oxLDL) which in turn further activate endothelial cells. Uptake of oxLDL by scavenger 
receptors on macrophages leads to foam cell formation, which leads to liberation of ROS and inflammatory 
cytokines, thus promoting further oxidation of LDL and endothelial dysfunction. This process may 
continue by SMC proliferation and migration from the media to the intima, as well as collagen deposition, 
creating a fibrous cap surrounding a lipid-rich necrotic core and dead or dying SMCs and macrophages. 
This constitutes the atherosclerotic plaque which leads to focal thickening of the media and restriction of 
blood flow, thus angina pectoris. Continuous monocyte influx, SMC proliferation and pro-inflammatory 
positive feedback, give rise to the more advanced atherosclerotic lesions. In acute coronary syndromes, 
matrix metalloproteinases (MMPs) digest collagen and cause thinning of the fibrous cap sequestering the 
lipid-laden core from the blood-flow, eventually resulting in plaque rupture and thrombus formation in the 
vessel.    
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 4.2 The role of inflammation in atherosclerosis and plaque 
destabilization
4.2.1 Inflammatory mediators – cytokines 
Cytokines are small proteins produced and secreted not only by immune cells but also by 
most cells in the organism, and mediate intercellular communication. They regulate 
fundamental biological processes via cell surface receptors, in autocrine, paracrine and 
sometimes endocrine manners. More than 100 cytokines are reported, conventionally 
classified into one of five families: interleukins (IL), interferons (IFN), colony 
stimulating factors (CSF), chemokines (chemotactic cytokines) and the tumor necrosis 
factor (TNF) superfamily, which will be discussed in detail below. Cytokines are of 
particular importance as regulators of the immune system. Due to considerable overlap 
between the families classified above, a subdivision is often preferred, such as dividing 
the cytokines with pro-inflammatory abilities (classically TNF, monocyte 
chemoattractant peptide (MCP)-1 IL-1, IL-6, IL-8 IL-12, IL-18 and INF), from those 
with largely anti-inflammatory abilities (including IL-4, IL-10, IL-13 and transforming 
growth factor [TGF]-). However, even this definition may be simplified. Thus, while IL-
4 and IL-13 hold anti-inflammatory properties by their ability to down-regulate 
inflammatory T helper cell type I (Th1) responses, they also are important pathogenic 
mediators in some inflammatory pulmonary disorders such as asthma.  Moreover, 
even if TGF are regarded as a potent anti-inflammatory cytokine, it also has 
32-35
monocyte/macrophage chemotactic properties with potential inflammatory consequences. 
In fact, even the classical anti-inflammatory cytokine IL-10 may, at least through long-
time exposure, induce inflammatory effects through its ability to promote B cell 
activation and antibody production.  
Cytokines share a number of specific features: i) They show pleiotropic activities; 
a cytokine can trigger several different cellular responses depending on cell type, timing 
and context. ii) They act synergistically; the association of two different cytokines (for 
example IL-8 and MCP-1) markedly amplifies their activity. iii) They act in an autocrine, 
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paracrine and juxtacrine manner; cytokines can stimulate the cells that produce them, 
adjacent cells, or through direct cell-cell interaction. This local mode of action sets 
cytokines apart from classical hormones. However, under certain circumstances 
characterized by severe inflammation, endocrine functions may also occur iv) They 
commonly share receptor subunits, and have to a large degree overlapping functions. v) 
Unique is also their tight regulation, separating them from growth factors, which tend to 
be more constitutively expressed.36 
4.2.2 Inflammatory diseases - too much of a good thing 
While inflammatory cytokines play an important protective role the immune response 
against foreign pathogens and cancer cells, excessive tissue production can mediate 
detrimental effects.37 Thus, enhanced production of inflammatory cytokines has been 
implicated in the pathogenesis of both acute (e.g., septic shock and cerebral malaria) and 
chronic (e.g., inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis and 
human immunodeficiency virus [HIV] infection) conditions.38, 39 While anti-
inflammatory type cytokines such as IL-10 ideally would limit the deleterious effects of 
inflammatory cytokines, prolonged IL-10 excess may promote progression of 
autoimmune diseases by enhancing B cell activity and autoantibody production, or 
immunodeficiency by deactivation of monocytes and macrophages.40, 41 Further, down-
regulation of TNF- in septic shock seems reasonable from an experimental point of 
view, since too much TNF- itself defines septic shock, but anti-TNF treatment was 
associated with increased mortality potentially due to “too much down-regulation” of this 
cytokine.39 Based on promising results in animal models, clinical trials using IL-10 
against inflammatory bowel disease and rheumatoid arthritis have been conducted, but 
shown opposing results.42, 43 Thus, the balance between beneficial and harmful effects of 
the same cytokine is of major importance from a therapeutical point of view.  
4.2.3 Atherosclerosis – an inflammatory disease 
Inflammation plays pivotal roles in all stages of atherosclerosis. The initial onset of 
atherosclerotic lesion development is related to blood flow disturbances, occurring at 
branch orifices, bifurcations and inner curvatures. At these sites, low or oscillatory blood 
flow induce endothelial cells, through shear stress responsive transcription factors, to 
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express adhesion molecules, chemokines and growth factors.44 The adhesion molecules, 
such as selectins (e.g., E-selectin and P-selectin), and members of the immunoglobulin 
superfamily (e.g., intercellular adhesion molecule-1 [ICAM] and vascular adhesion 
molecule-1 [VCAM]), which act as receptors for glycoconjugates and intergrins 
expressed on monocytes and T cells, and cause rolling and firm adhesion of leukocytes 
onto endothelial cells with subsequent migration of leucocytes into the intima.45 Flow 
disturbances may also directly induce MCP-1 expression in endothelial cells,44 which 
amplifies the recruitment and invasion of monocytes to the vascular wall.  
Once resident in the intima, monocytes differentiate into macrophages in response 
to macrophage colony stimulating factor (M-CSF)-stimulation, increase expression of 
scavenger receptors such as CD36 and scavenger receptor-A (SR-A) with subsequent 
enhanced uptake of modified lipoproteins such as oxLDL. Macrophages have a potential 
immunomodulatory capasity46 and secrete a wide range of cytokines, such as MCP-1 and 
IL-8, both potent chemoattractant chemokines that recruits leucocytes, as well as IL-12, a 
potent activator of T cells. The roles of T cells in the plaque are dual, due to T cell 
subsets with different effect on atherogenesis.47 Thus, while T cells are thougt to promote 
atherogenesis, there are also T cell subsets with potential anti-atherogenic properties, 
such as regulatory T cells (Treg, CD4+CD25+), specialized in suppression of pathogenic 
Th1 and Th2 responses against self and foreign antigens. Being a major source of the 
anti-inflammatory cytokines IL-10 and TGF-, Treg have been demonstrated as powerful 
inhibitors of atherosclerosis in several mouse models.48-50 In addition to cytokine-
dependent suppression of immune responses, Treg may also suppress pathogenic T cells 
through cell-cell contact-dependent mechanisms, particularly through engagement of 
cytotoxic T lymphocyte antigen (CTLA)-4 expressed on Treg with CD80/CD86 molecules 
expressed on effector T cells, or through interaction of CTLA-4 with CD80/CD86 on 
antigen presenting cells, leading to up-regulation of indoleamine dioxygenase and 
indirect down-regulation of effector T cell responses through tryptophan catabolism.51 
Moreover, Th2 cells have been associated with increased production of protective anti-
oxLDL antibodies, which are shown to reduce lesion size. 4, 52, 53 However, as discussed 
above, IL-4 may also have inflammatory properties and deficiency in IL-4 was recently 
shown to be associated with a decrease in atherosclerotic lesion formation, particularly at 
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the advanced stages of lesion progression.54 While the role of Th2 cells is debated, there 
is solid evidence from several independent groups that the Th1 subset is a particular 
proatherogenic subset within the CD4+ T cell population. First, a number of studies have 
co-localized CD4+ T cells and IFN  within human and mouse atherosclerotic lesions, 
suggesting predominance of Th1 cells in atherogenesis. 55-57 More recently, high levels of 
IL-12 and IL-18 mRNA and protein have also been detected in atherosclerotic plaques 
further suggesting a Th1 profile in these lesions.58 Second, a direct role in atherogenesis 
has been defined in atherosclerotic-susceptible mice that are deficient in either IFN 
receptors 59 or the cytokine itself.60 Conversely, injection of IFN or the IFN–releasing 
factors IL-12 and IL-18 enhances the extent of disease in apoE-/- mice.61 
However, the production of cytokines within an atherosclerotic plaque is not 
restricted to T cells and macrophages. In fact, all cell types present in the atherosclerotic 
plaque are potential contributors pro-inflammatory cytokines.36 Thus, endothelial cells, 
mast cells and even SMC has been shown to produce numerous cytokines and 
chemokines, promoting leukocyte migration and inflammation.  
4.2.4 Plaque-related inflammation: Promotion of matrix degradation 
and thrombus formation 
Within the atherosclerotic plaque, inflammation may have several pathogenic 
consequences, and its effect on matrix regulation and thrombus formation may be of 
particular importance. Thus, SMC respond to IL-1 and indirectly, to IFN with 
proliferation and migration to the site of the atherosclerotic plaque.62, 63 In the growing 
mass of extracellular lipid, intimal SMC migrate and deposit collagen and other 
extracellular matrix proteins, forming a fibrous plaque that protrudes in to the arterial 
lumen, eventually leading to formation of the fibrous cap surrounding the lipid-rich 
necrotic core that constitutes the atheroma. Moreover, the inflammatory cytokines 
produced during atherosclerosis significantly modulate the extracellular matrix 
composition, by affecting the expression of matrix metalloproteinases (MMPs) and their 
inhibitors tissue inhibitors of MMP (TIMP). Matrix degrading MMP production can be 
increased by oxidized lipids, reactive oxygen species, heat shock proteins, inflammatory 
cytokines and hemodynamic stress, all components existing in the plaque. Thus, 
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inflammation may lead to a shift of the plaque proteome toward matrix degradation, 
affecting plaque stability by thinning of the fibrous cap, leaving the plaque vulnerable to 
rupture. Cytokines also may promote thrombus formation within the lesion by causing 
enhanced expression of tissue factor (TF), a potent procoagulant, in plaque cells.64 
Moreover, cytokines can up-regulate plasminogen activator inhibitor (PAI)-1 and down-
regulate thrombomodulin, a potent endogenous anti-coagulant, further contributing to a 
prothrombotic state within the lesion. Hence, if the weakened cap ruptures, coagulation 
factors in blood gain excess of thrombogenic TF, causing thrombosis as described above. 
Moreover, due to cytokine-mediated effects on PAI-1 and thrombomodulin, the 
fibrinolytic and anti-thrombotic potential within the lesion will be decrased, further 
promoting thrombus formation at the site of plaque rupture.  
4.2.5 Immune-mediated plaque destabilization 
Two major types of physical disruption of the atherosclerotic plaque may occur.65 
Superficial erosion of the endothelial monolayer uncover subendothelial collagen and von 
Willebrand (vW) factor, promoting platelet adhesion and activation,66 thus making a 
nidus of a platelet thrombus formation with subsequent MI, counting for one-quarter of 
fatal coronary thromboses. The most common mechanism of plaque disruption involves 
rupture of the fibrous cap.30, 65 The thrombogenic, lipid-rich core of the plaque is 
normally sequestered from the blood-flow by the fibrous cap, but upon fissure formation, 
usually at the shoulders of the plaque, exposure and activation of the coagulation cascade 
in the blood vessel occurs, causing approximately three-quarters of all MI. Inflammation 
is instrumental in both of these mechanisms. First, endothelial erosion is linked to the 
proximity of highly activated subendothelial macrophages that may cause endothelial cell 
death by apoptosis and also weaken the endothelial intercellular integrity by producing 
MMPs. Second, a high content of SMC are thought to make the plaque less prone to 
rupture, and cytokine-induced apoptosis of these cells may also weaken the overall 
integrity of the plaque. Typical features of the vulnerable plaque are: a large lipid core 
occupying at least 50% of the plaque volume, a high density of macrophages, a high TF 
content, and low content of SMC and collagen in the fibrous cap.67 Although several cell 
types may contribute to these features of plaques at future risk, macrophage activation 
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seems to be of particular importance. Thus, the site of rupture is characterized by 
enhanced inflammation and often occurs in the macrophage-rich shoulder region.68 
Notably, plaque rupture is also influenced by external factors such as turbulence in 
passing blood, mechanical stress etc.65 Further, recent studies have shown that in addition 
to plaque size, the orientation of remodeling plays a role on vulnerability. Positive 
remodeling is characterized by “outward expansion”, that is, the plaque expands into the 
vessel wall, whereas negative remodeling encroach lumen. Positive remodeling is 
associated with unstable angina, whereas negative remodeling is more common in stable 
angina.69-71 Accordingly, several studies have suggested that in 60-70% of patients with 
ACS, the culprit site of the acute event had less than 70% (often under 50%) of vessel 
diameter narrowing.72  Thus, plaques producing non-flow-limiting and less than severe 
stenosis, accounts for more cases of ACS events than the severe stenotic plaques 
producing symptoms of stable angina. Moreover, recurrent coronary events, frequently 
occurring in ACS, are unrelated to the culprit lesion in almost half of the cases,73 
supporting the view of widespread diseased coronary vessels with multiple vulnerable 
plaques, reflecting widespread coronary inflammation.74, 75 It is also important to have in 
mind that, despite the body of evidence of a link from plaque vulnerability, rupture and 
ACS, many plaque ruptures do neither cause any occlusion of the vessel nor clinical 
symptoms.65 
4.2.6 Triggers of inflammation in atherosclerosis 
Chronic infections caused by for example Chlamydia pneumonia have been suggested to 
be involved in atherogenesis, and persistent stimulation by microbial antigens might well 
lead to enhanced inflammation within an atherosclerotic plaque. First, chronic 
extravascular infections (e.g. gingivitis and bronchitis) may augment production of 
inflammatory cytokines that may accelerate the evolution of remote atherosclerotic 
lesions.76-78 Second, many human plaques show sign of infection by microbial agents 
such as Chlamydia pneumonia,79-81 and indeed, infection with Chlamydia pneumonia has 
been found to accelerate atherosclerosis in rabbits on an atherogenic diet.82, 83 Chlamydia,
when present in arterial plaques, may release lipopolysaccharide (LPS) and heat-shock 
protein (Hsp) that can stimulate the production of inflammatory mediators in infiltrating 
 20 
leukocytes, vascular SMC and endothelial cells.84 Hsp, besides being molecular 
chaperons, are immunogenic molecules, and a significant element of the immune 
response to microorganisms is directed towards Hsp-derived peptides.85 Interestingly, 
both microbial antigens and Hsp may induce signaling through toll like receptors (TLRs). 
Thus, ligation of these receptors, defined as a key component of pathogen-associated 
molecular pattern recognition machinery, initiates activation of the transcriptional factor 
nuclear factor (NF)B resulting in the expression of a wide array of inflammatory 
genes.86-88 Interestingly, recent reports have shown that the expression of TLRs, in 
particular TLR1, TLR2 and TLR4, is markedly increased in human atherosclerotic 
lesions, and this enhancement occurs preferentially in endothelial cells and 
macrophages.89, 90 A recent study reporting an association between a decreased risk of 
atherosclerosis and TLR4 polymorphism, further supporting a role of TLRs in 
atherogenesis.91, 92 Moreover, in this study TRL4 polymorphism and decreased risk of 
atherosclerosis was not associated with decreased occurrence of bacterial infections, but 
with an attenuated inflammatory response to such infections. This finding suggests that 
rather than the microbes themselves, the inflammatory response to these microorganisms 
seems to be of major importance in the progression of atherosclerosis.  
However, the ”inflammation hypothesis” does clearly not depend on the 
”infection hypothesis”, and several other factors may lead to cytokine activation and 
inflammation within the atherosclerotic lesion.93 For example, modified autoantigens 
such as oxidized lipoproteins, human derived Hsp and reactive oxygen species (ROS), 
known to play a pathogenic role in CAD, might through monocyte activation or direct 
effects on T cells, also lead to increased production of inflammatory cytokines 
contributing the persistent inflammation within the atherosclerotic lesion.94 Classical risk 
factors for atherosclerosis, such as hypertension, hypercholesterolemia, smoking and 
diabetes mellitus share the ability to induce production of oxygen-free radicals, thus 
creating oxidative stress which in turn stimulate inflammatory gene expression.95 Further, 
oxidative stress mediates pro-inflammatory modifications of lipoproteins, which in turn 
are major stimulus of inflammation, leading to T cell activation94 and monocyte 
differentiation, as described above. Thus, it seems that several factors may contribute to 
the persistent inflammation within the atheroscleroticc lesion, including microbial and 
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non-microbial antigens as well as antigen-independent mechanisms (e.g., direct T cell 
activation by IL-7 and IL-15 96, 97). Moreover, even traditional risk factors seem to be 
operating, at least partly, through their ability to enhance inflammatory responses within 
the lesion, representing a common pathway for a wide range of pro-atherogenic factors. 
4.3 The TNF Superfamily
4.3.1 General background 
Based on their abilities to kill murine fibrosarcoma cells, the tumor necrosis factors 
gained their name in 1975, and about 10 years later the two archetypical TNF members 
were isolated and characterized, namely TNF- and lymphotoxin  (LT). Research 
during the last three decades have revealed several additional members, and the 
superfamily now consist of 20 members that signal through 29 different receptors.98 The 
TNF receptor superfamily (TNFRSF) are expressed by a wide variety of cells, while the 
TNF superfamily (TNFSF) ligands are known to be expressed predominately by cells of 
the immune system, including B cells, T cells, natural killer cells, granulocytes, 
monocytes and dendritic cells, but also by cardiomyocytes, bone-related cells and 
endothelial cells.98 The TNFSF have unique structural attributes that couples them 
directly to pathways for cell proliferation, differentiation and survival. Within the 
immune system, their rapid and potent signaling capabilities are crucial in coordinating 
the proliferation and protective functions of pathogen-reactive cells such as lymphocytes, 
granulocytes and macrophages. 
The TNF superfamily ligands are transmembrane type II proteins, with a C-
terminal receptor-binding extracellular domain, that may or may not be shredded by 
proteinases to yield a soluble form. Most members of the TNFRSF are type I 
transmembrane proteins, which share a structural hallmark of repetitive cystein-rich 
extracellular domains recognizing ligands. Functionally, TNFRSF members can be 
divided in three groups, according to their intracellular signal domains, containing either 
a death domain (DD), or a TNF receptor associated factor (TRAF) domain, or no signal 
domain. The first group, the “death receptors”, recruit intracellular death domain 
containing adaptors, such as Fas-associated DD protein (FADD) and TNFR-associated 
DD protein (TRADD), which activates the caspase cascade leading to apoptosis.  
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Figure 2.  
A presentation of the TNF superfamily ligands and their receptors; Ligand proteins have extracellular C-
terminal (type II transmembrane protein), which is known as the TNF homology domain and has 20-30% 
amino acid identity. Most ligands are released from cell surface by specific proteases. Receptors have N-
terminal extracellular domains (type I transmembrane protein) which is characterized by the presence 
cysteine-rich domains. Decoy receptors (DCRs) and osteoprotegerin (OPG) work as inhibitors of signaling. 
TNFR; Tumor necrosis factor receptor, DR; Death receptor, EDAR; ectodysplasin-A receptor, NGFR; 
nerve growth-factor receptor, RANK; receptor activator of nuclear factor B, LTR: lymphotoxin  
receptor, HVEM; herpes virus entry mediator, GITR; glucocorticoid-induced TNFR family receptor, 
BCMA; B-cell maturation antigen, TACI; transmembrane activator and cyclophilin ligand interactor, 
BAFF; B-cell activating receptor, XEDAR; X-linked EDA receptor, RELT; receptor expressed in lymphoid 
tissues, VEGI; vascular endothelial cell-growth inhibitor, TRAIL; TNF-related apoptosis-inducing ligand, 
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TWEAK; TNF-like weak inducer of apoptosis, LIGHT; lymphotoxin-like, exhibits inducible expression, 
and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes, APRIL; a 
proliferation inducing ligand, TRAF; TNFR-associated factor.   
 
The second group mediates effects associated with cell differentiation and proliferation, 
by recruiting TRAF family molecules, which activate signal mediators such as mitogen 
activated protein kinases (MAPK), extracellular signal-related kinase (ERK), 
phosphatoidyl-inositol-3 kinase (PI3K) and NFB. However, clear lines can not be drawn 
between the two groups; TRAF2, an activator of NFB which induce anti-apoptotic 
protein synthesis, binds almost all TNFRSF members, and recent discoveries indicate that 
any TNF signaling simultaneously activates both apoptotic and cell-survival signals, 
creating a balance of opposing signals that determine cell fate.98 Thus, TRAIL (TNF-
related apoptosis inducing ligand) and CD95L, two poor inducers of NFB, induce 
apoptosis more rapidly than TNF- does, whereas RANKL (receptor activator of NFB 
ligand) mainly provide survival signals through NFB. However, NFB does not only 
promote anti-apoptotic signaling, it also regulates pro-apoptotic signals through 
regulation of death receptors (DR1-6), and death receptor ligands such as CD95L, TNF- 
and TRAIL,99-102 illustrating the complexity of TNF-mediated cell survival signaling. 
The last group of receptors conducts no intracellular signaling, but are soluble 
decoy receptors, i.e., providing a level of regulation by competing with signal transducing 
receptors for ligands. Moreover, some receptors (CD27, CD30, CD40, 4-1BB, CD95, 
TNF receptor I [TNFRI] and TNFRII) can be found in a soluble form, with inhibitory or 
stabilizing effects on their corresponding ligand, further discussed below.  
The TNFSF regulates immunity at several levels, e.g., organization of lymphoid 
architecture103 and controlling the activity and survival of cytotoxic effector cells. 
Whereas they are physiologically crucial for normal responses, any inappropriate 
presence is harmful, and despite tight regulation, directly pathological contribution by 
several TNFSF ligands is described in numerous diseases. While TNF- is an essential 
element in host defense, excessive TNF- activity plays a pathogenic role in several 
inflammatory disorders such as inflammatory bowel disease, psoriasis and rheumatoid 
artithis, and therapeutic approaches that inhibit TNF- activity (i.e., soluble TNF receptor 
fusion protein or anti-TNF-antibodies) have been successful in the treatment of diseases 
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such as severe rheumatoid arthritis 104 and inflammatory bowel disease.105 TNF- is also 
suggested to be an important mediator of insulin resistance in obesity, thus playing a role 
in the development of type 2 diabetes mellitus,106 and is implicated in several of the 
pathophysiological processes that are thought to be important in the progression of 
chronic heart failure.107, 108 On the other hand, TNF- is of major importance in the host 
defense against certain intracellular microbes such as Mycobacterium tuberculosis, as 
illustrated in the increased frequency of mycobacterial infection in patients receiving 
anti-TNF therapy.109 Another TNFSF ligand, CD40L, is associated to immunodeficiency 
and autoimmunity due to reduced or increased levels, respectively,110 illustrating that 
both “too much” or “too little” of these ligands may be harmful. 
4.3.2 TNFSF in atherosclerosis 
Several TNFSF ligands have been linked to development of atherosclerosis. 
Experimental studies using atherosclerosis-prone apolipoprotein E deficient (apoE-/-) 
mice crossed with TNF-/- mice, thus creating a double knockout, have shown that 
atherosclerotic lesion size is significantly smaller in the double knockout than in that of 
apoE-/- mice, associated with decreased expression of ICAM-1, VCAM-1 and MCP-1.111 
However, anti-atherogenic properties of TNF- has also been reported. Thus, in TNFRI-
deficient atherosclerosis-prone C75BL/6 mice fed with atherogenic diet, developed 
lesions were larger than wild type C75BL/6 mice, suggesting a protective role of TNFRI 
signaling.112 However, in vivo analysis have shown TNF- expression in the shoulder 
region of the plaque, associated with CD68-positive foam cells.113 Moreover, TNF- was 
expressed more abundantly in regions with a thin fibrous cap (atheromatous regions) 
compared to more fibrous regions, contributing to matrix degradation via MMP 
activation and pro-thrombogenicity by promotion of TF production in monocytes.113, 114 
 In addition to TNF-, the TNFSF member CD40L and its receptor CD40 have 
attracted much attention as potential therapeutical targets of atherogenesis. The 
immunomodulatory dyad CD40L/CD40, present on endothelial cells, vascular SMC, 
macrophages, T cells and platelets within human atheroma, has been implicated in several 
aspects of atherogenesis and ACS.115, 116 CD40Lwas originally identified on CD4+ T 
cells, but has recently also been found on mast cells, basophils, eosinophils as well as on 
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activated platelets.117 Both membrane-bound and soluble (s) forms of this ligand may 
interact with CD40, which is constitutively expressed on B cells, macrophages, 
endothelial cells and vascular SMC, resulting in various inflammatory responses with 
relevance to atherogenesis. Thus, in vitro activation of CD40L-CD40 signaling in 
atheroma-derived cells results in production of chemokines and other cytokines, TF, 
MMPs and adhesion molecules.118, 119 In vivo, an important role for CD40L-CD40 
interaction in the progression of atherosclerosis was demonstrated using mice deficient in 
CD40L and apoE showing a dramatic decrease in plaque area compared with normal 
apoE-deficient animals.120 Moreover, advanced atherosclerotic lesions of these mice 
showed a lipid-poor collagen-rich stable plaque phenotype, with reduced macrophage and 
T cell content. The possible plaque stabilizing effect of CD40L neutralization was further 
demonstrated in another study showing that administration of anti-CD40L antibody to 
apoE-deficient mice induced a stable plaque phenotype both at the onset of 
atherosclerosis and after development of advanced plaques.121 Recently the list of 
biological activities of CD40L was extended from regulation of immune responses to 
induction of platelet activation and thrombus formation.122 Hence, CD40L appears to 
stabilize arterial thrombi by an integrin-dependent mechanism, and the absence of 
CD40L may delay arterial occlusion in vivo.123 It is unclear whether both the 
transmembrane and the soluble (s) forms of CD40L are active in promoting platelet 
activation, but recombinant sCD40L alone was shown to enhance integrin-mediated 
platelet aggregation at high shear rates restoring normal thombosis in CD40L-/- mice.123 
Several groups have reported enhanced serum levels of sCD40L and increased expression 
of membrane-bound CD40L on T cells and platelets in angina patients, with particularly 
high levels in those with unstable disease.115, 124 These activated platelets and T cells in 
unstable angina may, by providing CD40L, contribute to inflammatory reactions, MMP 
activation and pro-coagulant activity within an atherosclerotic plaque. Such activities 
may in turn further enhance platelet and T cell activation as well as thrombus formation, 
possibly representing a pathogenic loop promoting plaque destabilization and rupture 
during ACS.115, 117 Recently, Bavendiek et al. suggested that CD40L derived from non-
hematopoietic cell types may be of even more pathogenic importance in atherogenesis 
than T cell or platelet-derived CD40L.125 Nevertheless, this ligand, which has the unique 
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property of both promoting inflammation and thrombus responses, activating both 
endothelial cells, leukocytes and platelets, operating in a self-perpetuating feedback loop, 
should be further investigated as a therapeutic target in atherosclerotic disorders.  
5. Aims of the study 
While the role of inflammation in atherosclerosis is well established, the relative 
importance of the various mediators, as well as their effector mechanisms, is far from 
clear. While several studies have focused on the role of the CD40L/CD40 dyad in 
atherogenesis and plaque destabilization, we hypothesized that also other members of 
TNFSF could be of pathogenic importance in these processes. In the present study this 
hypothesis was investigated by several experimental approaches including studies in well 
characterized patients with stable and unstable angina, studies in experimental 
atherosclerosis as well as in vitro studies in cells with relevance to atherogenesis such as 
endothelial cells, platelets, macrophages and vascular SMC. 
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6. Summary of results 
Paper I 
Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible 
role in plaque destabilization. RANKL, its membrane-bound receptor RANK and its 
soluble decoy receptor osteoprotegerin (OPG) are members of the TNFRSF. These 
factors have been identified as mediators of paracrine signaling in bone metabolism but 
are also involved in modulation of the immune response. We found that serum levels of 
OPG were raised in patients with unstable angina (n=40), but not in those with stable 
angina (n=40), compared to controls (n=20). Further, mRNA levels of RANKL were 
increased in T-cells in unstable angina patients accompanied by increased expression of 
RANK in monocytes. Strong immunostaining of OPG/RANKL/RANK was seen within 
thrombus material obtained at the site of plaque rupture during acute MI. Moreover, 
OPG/RANKL/RANK was expressed in the atherosclerotic plaques of apoE–/– mice, with 
RANKL located specifically to the plaques. In vitro, RANKL enhanced the release of 
MCP-1 in mononuclear cells from unstable angina patients, and MMP activity in vascular 
SMC. We propose a role of T cell mediated RANKL in the destabilization of 
atherosclerotic plaques, acting atherogenic by promoting inflammatory and matrix-
degrading mechanisms. 
Paper II 
Enhanced plasma levels of LIGHT in unstable angina – possible pathogenic role in 
foam cell formation and thrombosis. Several inflammatory mediators including TNFSF 
members have been reported to increase after oxLDL stimulation of macrophages. Our 
results showed that the TNFSF member LIGHT (homologous to lymphotoxins, shows 
inducible expression, and competes with herpes simplex virus glycoprotein D for 
herpesvirus entry mediator, a receptor expressed by T lymphocytes) was markedly up-
regulated in oxLDL-stimulated THP-1 macrophages, assessed by microarray and real 
time quantitative RT-PCR analysis. Underscoring these in vitro findings, we found 
enhanced plasma levels of LIGHT in angina patients, with particularly high levels in 
those with unstable disease. Stimulation with LIGHT enhanced lipid accumulation in 
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oxLDL stimulated THP-1 macrophages, probably through an up-regulation of the 
scavenger receptor SR-A. Moreover, upon LIGHT-stimulation, THP-1 macrophages as 
well as monocyte-derived macrophages were transformed into pro-thrombotic 
phenotypes, shown by increased expression of TF andPAI-1 as well as enhanced 
thrombin formation. Finally, he LIGHT-mediated enhancement of SR-A and TF 
expression appears to involve NF-B activation. Our findings suggest that LIGHT could 
be involved in atherogenesis and plaque destabilization by promoting foam cell formation 
and thrombus formation. 
Paper III 
Inflammatory interaction between LIGHT and Proteinase-activated reseptor-2 in 
endothelial cells – potential role in atherogenesis. The interaction between 
inflammatory cytokines and endothelial cells is a critical step in atherogenesis leading to 
endothelial cell dysfunction and enhanced inflammation. In the present study we 
identified proteinase-activated receptor 2 (PAR-2) as an inflammatory mediator that was 
markedly enhanced by LIGHT in endothelial cells. We also found that LIGHT acted 
synergistically with PAR-2 activation to promote enhanced release of the pro-atherogenic 
chemokines IL-8 and MCP-1, underscoring the interaction between LIGHT and PAR-2 
as biologically active, promoting potent inflammatory effects. We showed that the 
LIGHT-mediated up-regulation of PAR-2 in endothelial cells is mediated through the 
HVEM receptor, dependent on Jun N-terminal kinase and NF-B intracellular signaling 
pathways. A LIGHT-mediated up-regulation of PAR-2 mRNA levels was also found in 
human macrophages. We have previously demonstrated increased plasma levels of 
LIGHT in unstable angina patients (paper II), and here we show a similar pattern for 
PAR-2 expression in peripheral blood monocytes. We also found that LIGHT, LIGHT 
receptors, and PAR-2 all showed enhanced expression, and in some degree co-
localization in endothelial cells and macrophages, in the atherosclerotic plaques of ApoE-
/- mice, suggesting that the inflammatory interaction between LIGHT and PAR-2 also 
may be operating in vivo within an atherosclerotic lesions. Our findings suggest that 
LIGHT/PAR-2 driven inflammation could represent a pathogenic loop in atherogenesis.  
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Paper IV 
Platelets release the tumor necrosis factor superfamily ligand APRIL (TNFSF13) 
upon activation – increased expression of APRIL in coronary and carotid 
atherosclerosis. Blood platelets are regarded as important contributors to the 
development of atherosclerosis, not only through their role in thrombus formation, but 
also through their ability to promote inflammation. Thus, activated platelets release a 
wide range of inflammatory mediators, including members of the TNFSF (e.g., CD40L 
and LIGHT). In the present study we demonstrated that platelets release the TNFSF 
ligand A proliferation-inducing ligand (APRIL) upon thrombin receptor activation. Upon 
SFLLRN activation, there was a gradual release of APRIL reaching maximum after 90 
minutes. This long-lasting release, which follows the same pattern as previously shown 
for the solubilization of CD40L and LIGHT, differ from an ordinary -granule release 
where the granule components are fully released within less than 10 minutes. However, 
while the gradual release of APRIL is similar to the release pattern of sCD40L and 
LIGHT, our data show that the release of APRIL is quite differently regulated. Thus, 
whereas the release of LIGHT and sCD40L involves GP IIb/IIIa-dependent mechanisms 
and action of metal-dependent proteases as well as intracellular processes such as actin 
polymerization, this seems not to be the case for the release of APRIL. The release of 
APRIL in SFLLRN activated platelets was totally abolished when prostaglandin E1 
(PGE1) was added to the suspension 20 minutes prior to activation. In contrast to the 
release of CD40L and LIGHT, PGE1 could not modulate APRIL release when added to 
platelets 10 minutes after stimulation. Although APRIL mRNA in platelets was 
demonstrated, APRIL release was not blocked by cycloheximide, an inhibitor of protein 
synthesis. With relevance to atherogenesis, we found that patients with CAD had raised 
plasma levels of APRIL as compared with controls, and APRIL immunoreactivity was 
detected in aggregated platelets within the ruptured plaque in patients with STEMI and 
within macrophages in symptomatic carotid plaques. Our findings suggest that APRIL 
should be added to the list of platelet-derived soluble inflammatory proteins. The 
enhanced expression of APRIL in atherosclerotic disorders, both systemically and within 
the lesion, may suggest the involvement of APRIL in atherogenesis and plaque 
destabilization.  
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7. Discussion 
7.1 Methodological considerations 
7.1.1. Individuals 
All patients included in this thesis had verified CAD, as assessed by coronary 
angiography showing at least one vessel disease (>50% narrowing of luminal diameter) 
and as a major objective was distinction between stable and unstable angina, a 
comprehensive characterization of the patient groups were conducted. Patients with 
unstable angina all fulfilled the criteria of Braunwald class IIIb, none had elevation of 
CK-MB, but some had increased levels of cardiac troponins, reflecting minimal 
myocardial necrosis. Average TIMI risk score for the patients with unstable angina used 
in paper I, II and IV was 3.13, representing a 5-13% risk of cardiovascular events (MI or 
death) within 14 days.126 Enhanced inflammatory activity in these patients may reflect 
enhanced inflammation in the atherosclerotic plaques, or may be a consequence of 
minimal myocardial damage. This issue should be of consideration when evaluating 
measurements of circulating inflammatory markers in this patient population. The stable 
angina patients had stable effort angina NYHA class II or III and a positive exercise test. 
The diagnosis of CAD was confirmed in all patients by coronary angiography (see 
above), thus excluding patients with symptoms of angina pectoris without significant 
CAD. Standard medical therapy including -adrenergic antagonist (83-100%), aspirin 
(75-92%) or warfarin, statins (80-86%) and to a lesser degree calcium antagonist (11-
22%), nitrates and angiotensin-converting enzyme (ACE) inhibitors was used by the 
patients. According to standard procedures, unstable angina patients had received heparin 
or low-molecular weight heparin before inclusion, but this medication had been 
discontinued >12 hours before blood sampling. Nevertheless, heparin therapy may 
increase the plasma/serum levels of cytokines and in particular chemokines127, but not the 
mRNA levels in PBMC as examined in the present study. Moreover, effect of heparin on 
plasma levels of cytokines seems primarily to occur within minutes or hours with no or 
only minor effects after 12 hours. As for most of the other medications such as statins, 
ACE inhibitors and inhibitors of platelet activation, down-regulatory effects on 
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inflammatory cytokines may be expected, resulting in underestimation rather than 
overestimations of differences in levels of inflammatory mediators between patients and 
controls. Finally, to exclude patients with causes of systemic inflammatory activation 
other than CAD, patients with concomitant disease such as congestinal heart failure, 
infections, lung diseases cancer or autoimmune disorders were not included in the 
studies. Also, patient with MI <6 weeks before blood sampling were excluded due to 
persistent systemic immune activation after such an event. 
7.1.2 Isolation and culturing of cells from peripheral blood 
A main focus in the present thesis was the study of mononuclear cells from peripheral 
blood, i.e., peripheral blood mononuclear cells (PBMC), T cells and monocytes. A 
problem with such studies can be ex vivo activation of cells during the isolation 
procedures. First, contamination of collection tubes, buffers and media with endotoxins 
and microorganisms may activate the cells and induce cytokine expression. Second, the 
blood sampling technique and differences in blood withdrawal speed as well as isolation 
of PBMC by density gradient centrifugation over Ficoll-Hypaque may influence the gene 
expression of cytokines in these cells. In the present study, T cells and monocytes were 
isolated from PBMC using well established methods that minimize ex vivo activation. 
Thus, T-cells were isolated using negative selection, while monocytes were isolated using 
CD14-labeled paramagnetic microbeads. This positive selection of monocytes could 
potentially induce cell activation via CD14 engagement, but the use of microbeads and 
low temperature (i.e., 4ºC) during the separation procedure have been shown to promote 
negligible monocyte activation. To further assure minimal differences in ex vivo 
activation in the isolation of cells from patients and healthy controls, all blood sampling 
and cell isolation protocols were standardized and cell isolation was performed under 
sterile conditions and only sterile and endotoxin-tested (endotoxin-levels< 10 pg/ml) 
materials were used. After isolation, the cells were snap-frozen and stored on liquid 
nitrogen, or used directly in cell culture experiments. Notably, gene expression of 
cytokines known to be promptly up-regulated after various forms of activation such as 
hypoxia (e.g., IL-8 and TNF-) were only weakly expressed in isolated cells from healthy 
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control subjects, indicating that any differences in gene expression observed in patients 
are related to in vivo and not ex vivo activation.    
7.1.3 Measuring of cytokines in blood 
Factors related to blood collection and processing that may influence the measured 
cytokine levels in plasma and serum include procedure for blood collection, 
contamination of collection tubes, buffer and media, time before storage, temperature 
during storage and freeze thaw cycles.128, 129 However, the effect of these influencing 
factors may be reduced by using sterile and endotoxin-free collection tubes, buffers and 
media, immediate execution of separation protocols and freezing, and by freezing and 
thawing the samples less than three times.128, 129 In the present study we consistently 
adhered to these standards. Moreover, the measured levels of cytokines may be affected 
by the choice of anti-coagulant (plasma), and the release of cytokines from platelets 
during ex vivo coagulation (serum). In general, it has been reported that recovery of 
cytokines is more optimal from plasma than from serum, and that EDTA should be 
preferred as an anti-coagulant as it seem to inhibit ex vivo cytokine production during 
plasma preparation.128, 129 Furthermore, examination of cytokines that may be present in 
platelets, such as LIGHT and APRIL should be performed in platelet-poor plasma, to 
avoid release of cytokines from platelets ex vivo during the thawing procedure. In this 
work cytokine measurments were performed according to these precautions.  
7.1.4 Enzyme Linked Immunosorbent Assays (ELISAs) 
Commercially available ELISAs were used for measuring the protein levels of cytokines 
in this study. ELISAs are widely used as they are easy, time sharing and specific, but 
some considerations should be mentioned. First, immunoassays may detect both active 
and inactive forms of a protein, potentially giving the wrong impression of ongoing 
biological processes. Second, the recognition profile of the antibodies will vary between 
ELISA kits and manufacturers. Third, the presence of soluble cytokine receptors, 
cytokine antibodies and binding proteins in the biological sample might affect the 
measured cytokine levels. In this study, data were only compared when using the same 
ELISA kits from one manufacturer. Further, when comparing groups (e.g., controls vs. 
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stable and unstable angina patients), all groups were represented on any microtiter plate 
to minimize run-to-run variability when interpreting group-to-group variations.  
7.1.5 mRNA measurements  
RNA was isolated using silica-gel based membranes (RNeasy columns) or by MagNA 
Pure LC robot. RNA concentration and purity was evaluated by measuring the 
absorbance at 260/280 and 260/230 nm using nanodrop spectrophotometer. Only samples 
of high integrity and purity were further analyzed. For quantification and comparison of 
the mRNA transcripts in question, we used real time quantitative reverse transcriptase 
PCR (qPCR). This method is based on a fluorogenic dye (or sequence specific probe) 
which emits detectable fluorescence proportionally to the increasing amount of PCR-
products produced in a 40 cycle reaction. Gene expression was for each sample 
normalized to -actin, which at least theoretically is stably expressed in a wide range of 
conditions and cell types, thus obtaining an intra-sample relative expression value for the 
gene in question. Sample-to-sample variations were minimized by loading approximately 
equal amounts of RNA into the reverse transcriptase reaction. Further, to avoid 
misinterpretation of data because of assay-to-assay variations, all samples from one 
experiment were analyzed in one assay. By using cDNA microarray we were able to 
analyze expression of several thousand genes simultaneously. This technique has 
limitations in reliability related to data collection, analysis and validation, therefore used 
for hypothesis generation. Candidate genes were identified by this method in paper III 
and IV in this thesis, and all gene expression data derived from microarrays were 
confirmed by qPCR.  
7.2 RANK ligand in atherosclerosis 
7.2.1 RANK ligand and T cells 
In paper I, we showed enhanced expression of RANKL in T cells from patients with 
unstable angina. A pathogenic role of T cells in atherosclerosis is well established, and 
some recent studies suggest that this also may involve certain members of the TNF 
superfamily as co-stimulators for T cell activation.130 Our findings in the present study 
suggest that RANKL-RANK interaction involving T cell-related mechanisms also could 
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be involved in atherogenesis. RANKL expression has previously been detected in 
activated T cells, and as a key regulator of bone metabolism. In fact, RANKL is highly 
expressed by osteoblast/stromal cells, and essential in osteoclast activation. However, T 
cell-derived RANKL has also been demonstrated to modulate immune responses, 
lymphocyte maturation and lymph node organogenesis.131-137 RANKL signals through its 
transmembrane receptor RANK, which is mainly expressed by monocyte/macrophage 
lineage cells, including dendritic cells, osteoclasts and their precursors, to generate 
multiple intracellular signals that affect cell differentiation, function and survival.138-141  
Kanamaru et al showed that RANKL was rapidly shed by the metalloprotease-disintegrin 
TNF- convertase (TACE), or a related metalloprotease, from the T cell membrane in 
both in vitro activated T cells and from T cells in inflammatory tissues (rheumatoid 
synovium).137, 142 In paper I, we documented strong immunostaining of RANKL in 
atherosclerotic plaque, and in thrombus material. Although its receptors RANK and OPG 
were found in healthy vessel wall, RANKL was specifically related to the plaque, and 
associated to the T cell and macrophage-rich core region. Moreover, we showed that 
mRNA expression of the signal-transducing RANKL receptor, RANK, was significantly 
higher in monocytes from patients with unstable angina, and non-significantly increased 
in T cells from the same patient group. Taken together, these findings are indicative for 
paracrine signaling by T cells of the atherosclerotic plaque, involving RANKL-RANK 
interaction, with consequences discussed below. 
7.2.2 RANKL and its soluble receptor osteoprotegerin (OPG) 
Soluble TNF receptors are typically considered to act as inhibitory regulators of TNF-
signaling, by competing with signal-transducing cell surface TNF receptors. OPG is a 
soluble decoy receptor binding RANKL and TRAIL. In bone, RANKL promotes the 
resorptive activity and survival of mature osteoclasts, and OPG counteracts these 
RANKL-RANK mediated actions by binding RANKL, and the RANKL-to-OPG balance 
critically determinate bone remodeling and net bone mass. However, as discussed above, 
the effect of RANKL-RANK interaction is not restricted to bone metabolism. Hence, the 
RANKL/RANK/OPG axis has been discussed as the molecular link between skeletal, 
immune and vascular diseases,143 and raised circulating levels of OPG are reported in 
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CAD patients with increasing levels according to disease severity.144 OPG levels have 
also been shown to be a reliable predictor of forthcoming cardiovascular events in 
various study populations.144-147 In paper I, we showed significantly raised serum levels 
of OPG in unstable but not in stable angina, further supporting these findings. Strong 
immunostaining of OPG in vulnerable atherosclerotic plaques further implicate the 
RANKL/RANK/OPG axis in atherogenesis. These findings may also suggest that the 
reliability of OPG as a marker of atherosclerotic disorders could reflect that 
plasma/serum levels, at least partly, are derived from the atherosclerotic lesion. 
Furthermore, while primary thought to inhibit the binding of RANKL to its receptor 
RANK, we show in paper I that OPG may also enhance the RANKL-inducing effects on 
MMP activity in vascular SMC, at least under high RANKL/OPG ratio. A similar 
stabilizing or enhancing effects on its corresponding ligand has also been demonstrated 
for soluble TNF-Rs.148-151 Moreover, we also found that OPG had MMP-inducing effects 
in SMC on its own, further challenging the view that OPG is solely a RANKL inhibitor. 
The ability of OPG to induce MMP activity and in particular MMP-9, has recently been 
supported by others.152 
7.2.3 RANKL and plaque destabilization 
Several findings point at the RANKL/RANK/OPG axis as a contributor to plaque 
destabilization. First, increased RANKL expression on T cells was prominent in the 
unstable patient group. Second, Golledge et al reported OPG to be expressed at higher 
levels in symptomatic than in asymptomatic atherosclerosis,153 and we extended these 
findings by demonstrating enhanced RANKL immunostaining in plaques from apoE-/-
xCD4dnTßRII mice (i.e., ApoE-/- mice that are lacking the TGF-ß receptor on T cells), 
which develop a more severe atherosclerotic phenotype relative to apoE-/- mice. These 
findings were supported by strong immunostaining of the RANKL/RANK/OPG triad in 
thrombus material obtained from the site of plaque rupture in patients undergoing PCI. 
Third, during PCI, a mechanically induced plaque rupture, we found increased RANKL 
expression in PBMC, further suggesting that increased RANKL expression is a feature of 
unstable disease. Moreover, the RANKL-induced MCP-1 release was significantly 
elevated in PBMC from unstable angina as compared to stable angina patients and 
 36 
healthy controls, potentially reflecting enhanced RANK expression on monocytes in 
unstable patients. Chemotactic properties of RANKL on monocytes have previously been 
reported by others, acting additively to MCP-1.154 We further showed that RANKL and 
OPG induced MMP activity in SMC, both alone and in a cooperative manner. Taken 
together, a functional, pathogenic picture emerges, where the RANKL/RANK/OPG axis 
could contribute to some of the hallmark features of plaque destabilization, namely 
recruitment of inflammatory cells and degradation of the fibrous cap. However, RANKL 
has also been shown to protect endothelial cells against apoptosis,155 a property with 
potential anti-atherogenic properties. Moreover, studies in OPG-/-apoE-/- mice as well as 
in LDL receptor (LDLR)-/- mice treated with recombinant OPG suggest a role for OPG in 
vascular calcification rather than plaque stability,152, 156 underscoring that these issues 
will have to be further clarified, including studies in apoE-/- or LDLR-/- mice over-
expressing or lacking RANKL or RANK. 
7.3 A proliferation inducing ligand (APRIL) in atherosclerosis 
7.3.1 Platelet-mediated inflammation 
Several lines of evidence support a role for platelets as inflammatory cells. Platelets 
provide a wide range of growth factors and inflammatory mediators which are released 
mainly from the intracellular storage granules upon activation. These include several 
chemokines such as chemokine platelet factor-4 (PF-4), -thromboglobulin, Regulated 
upon Activation Normal T cell Expressed and Secreted (RANTES), growth-regulated 
oncogene- (GRO- ), epithelial neutrophile activating peptide-78 (ENA-78) and 
neutrophil activating peptide (NAP-2) as well as IL-7, a cytokine with the ability to 
induce T cell activation without the presence of antigens.96, 157-160 These soluble ligands 
may together with membrane-bound mediators expressed on the platelet surface upon 
activation (i.e., P-selectin), promote inflammatory responses in adjacent monocytes 
involving NFB activation. Moreover, recent studies suggest that platelets also may 
modulate the function of other leukocyte subsets (i.e., natural killer cells, granulocytes, T 
cells), and they have been found to enhance chemotactic and adhesive properties of 
endothelial cells as well as IL-1 production in vascular SMC.161, 162 Finally, platelets may 
themselves respond to inflammatory mediators. In fact, platelets have recently been 
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found to express several chemokine receptors that upon stimulation enhance platelet 
activation.163 Hence, during activation platelets may not only promote thrombus 
formation, but seem also to release and express inflammatory mediators, induce an 
inflammatory response within leukocytes and endothelial cells, and respond with 
activation to several of the inflammatory mediators produced by these cells. Such 
platelet-mediated inflammation seems to play a pathogenic role in atherosclerosis as well 
as in other inflammatory disorders. Thus, platelets co-localize with monocytes in early 
stages of atherosclerosis,164 and platelet-leukocyte interaction appears also to be involved 
in plaque destabilization during ACS as well as in the pathogenesis of various bacterial 
infections and various forms of vasculitis.165-167 
7.3.2 TNF superfamily and platelet-mediated inflammation 
Several members of the TNF superfamily are also reported to be expressed by platelets, 
and to date, CD40L, FasL, TRAIL and LIGHT are described.122, 168-170 While the 
biological activity of platelet-derived soluble TNFSF members has been an issue of 
controversy, membrane-bound CD40L on platelets is shown to be involved in initiation 
of an inflammatory response at the vessel wall by inducing adhesion molecules and 
secretion of chemokines in the vascular endothelial cells.122, 165, 171 Some studies have 
also suggested biological roles for sCD40L. Thus, Zhang et al reported that sCD40L 
released from platelets is able to activate fibroblasts in vitro, as indicated by regulation of 
cyclooxygenase (COX)-2 expression.172 Aukrust et al reported that serum-derived 
sCD40L could induce MCP-1 in PBMC, and these authors have also showed the ability 
of sCD40L to promote inflammatory and pro-thrombotic responses in endothelial 
cells.115, 166, 173 Moreover, André and colleagues demonstrated that recombinant sCD40L 
alone could enhance integrin-mediated platelet aggregation at high shear rates restoring 
normal thrombosis in CD40L-/- mice.123 These authors have more recently suggested that 
sCD40L is a ligand for GP IIb-IIIa inducing platelet stimulation as evidenced by the 
generation of platelet microparticles and by the activation of the receptor function of GP 
IIb-IIIa for soluble fibrinogen, whereas secretion from - and dense granules was not 
observed.174 As for platelet derived FasL, both membrane bound and soluble forms have 
been reported, but so far, its biological effect has been restricted to the membrane-bound 
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form promoting apoptosis in Fas-positive cancer cells.168 While surface expression and 
release of TRAIL from activated platelets are documented, 169 no biological functions of 
platelet-derived TRAIL have been described yet. Recently, Otterdal et al showed that 
LIGHT was released from platelets upon activation.170 This study also showed that 
platelet-derived soluble LIGHT was able to induce IL-8 and MCP-1 release from 
endothelial cells as well as monocytes. In paper IV we demonstrate that APRIL, another 
member of the TNF superfamily, is released by platelets upon activation.  
7.3.3 Platelet-derived APRIL  
In contrast to the rapid release of -granule contents from activated platelets, APRIL was 
released in a gradual and long lasting manner, showing a similar release pattern as 
previously described for other TNFSF members (e.g., CD40L and LIGHT).170, 175-177 
López-Fraga et al demonstrated that APRIL is synthesized as a transmembrane protein 
and cleaved to its soluble and biologically active form by furin, a pro-protein convertase. 
Further, using human embryonic kidney (HEK) 293T cells, these authors demonstrated 
that processing of APRIL occurs in the golgi apparatus and is subsequently released as a 
soluble protein.178 In platelets however, blocking experiments using both membrane 
permeable and impermeable furin inhibitors did not affect APRIL release upon 
activation. Further, brefeldin A, a golgi-disturbing agent, did not block the release of 
APRIL upon platelet activation. Platelets contain megakaryocytic mRNA and ribosome 
apparatus, and platelet protein synthesis is previously described.179 We detected APRIL 
mRNA transcripts in purified platelets, but inhibition of translation using cycloheximide 
did not attenuate APRIL release from activated platelets. We have previously shown that 
inhibitors of calcium dependent MMPs and disintegrin and metalloproteinases (ADAMs) 
(i.e., EDTA [a strong calcium chelator] and GM6001 [a hydroxamate inhibitor of 
MMPs], and inhibitors of actin polymerization (cytochalasin D) markedly attenuate the 
platelet-mediated release of sCD40L and LIGHT.170, 177 However, none of these 
substances influenced the release of APRIL in SFLLRN activated platelets, even when 
added to PRP 20 minutes before activation. Moreover, in contrast to our previous reports 
on sCD40L and LIGHT, Glanzmann's thrombasthenia, an inherited deficiency of GP 
IIb/IIIa, did not influence the release of APRIL in SFLLRN activated PRP. Prostaglandin 
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E1 (PGE1) is an effective platelet inhibitor, acting through its ability to raise intracellular 
cAMP levels and thereby decreasing intracellular Ca2+ levels. We were able to block 
APRIL release by incubating the platelets with PGE1 for 20 minutes prior to SFLLRN 
activation. This blocking effect was however not achieved when adding PGE1 15 minutes 
after platelet activation, as we have previously shown for sCD40L and LIGHT,170, 177  
indicating an exclusive release mechanism for APRIL compared to other TNFSF ligands.   
7.3.4 Physiologic and pathophysiologic effects of APRIL  
APRIL and its closely related B cell-activating factor of the TNF family (BAFF), have 
several features in common, they are both expressed in monocytes and macrophages, and 
both participate in stimulation of peripheral B cell and plasma cell survival and 
proliferation by binding to their respective receptors; APRIL binds B cell maturation 
antigen (BCMA) and proteoglycans, BAFF binds BAFF-receptor (BAFFR), whereas 
both BAFF and APRIL binds transmembrane activator and CAML interactor (TACI).180-
182 The relative importance of BAFF and APRIL in immune responses are largely 
unknown,181 but interestingly, we showed increased levels of APRIL but not BAFF 
(Sandberg WJ, Aukrust P, unpublished data) in plasma from angina patients.  
APRIL is a known regulator of normal B cell development and function.183 It has 
also been shown to promote T cell activation as well as to induce the up-regulation of 
several key co-stimulatory molecules on B cells, and thereby significantly enhancing 
their antigen presentation function.183 Recent studies have suggested an important role for 
APRIL, not only in normal immune responses, but also in the establishment and/or 
maintenance of autoimmune and inflammatory diseases. Thus, altered circulatory levels 
of APRIL have been reported in several inflammatory disorders. Koyama et al reported 
raised serum APRIL in systemic lupus erythematosus,184 and both APRIL and BAFF 
levels are associated to Sjogren’s syndrome.185, 186 APRIL levels were also elevated in 
synovial fluid from patients with inflammatory arthritis.187 However, APRIL levels 
within the inflamed synovia did not correlate to serum levels, indicating that APRIL may 
be produced and potentially play an active role at the sites of inflammation.  
 In paper IV we show that patients with CAD had raised plasma levels of APRIL 
as compared with healthy controls, and with relevance to the role of platelet-derived 
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APRIL, APRIL immunoreactivity was found in aggregated platelets within the ruptured 
plaque in STEMI patients. Moreover, strong APRIL immunostaining was found within 
macrophages in symptomatic carotid plaques. The pathogenic consequences of this 
finding is at present unclear, but based on its ability to enhance T cell activation as well 
as to down-regulate apoptosis in these cells, promoting an long-lived inflammatory 
phenotype,183 it is tempting to hypothesize that APRIL could contribute to T cell-related 
inflammation within the atherosclerotic lesion.  
Several studies support a role of APRIL in B cell function, converting subliminal 
B cell activation to a productive response.183 However, while the role of macrophages 
and T cells in atherogenesis is well established, the role of B cells is less studied. Only a 
few B cells are detected in atherosclerotic plaques, but substantial amounts of B cells and 
plasma cells are found in periadventitial lymphoid infiltrates surrounding advanced 
lesions.188, 189 Several lines of evidence support the hypothesis that humoral immunity 
protects against atherosclerosis. Thus, splenectomy (i.e., removal of the B cell–rich 
spleen) increases lesion development in apoE/ mice, whereas B cell transfer from 
atherosclerotic to splenectomized apoE/ mice ameliorates atherosclerosis.190 These 
effects may depend at least partly upon the production by B cells of antibodies against 
candidate antigens, including oxLDL.191 On the other hand, it has also been suggested 
that B cells could promote inflammatory responses within an atherosclerotic lesion 
through production of antibodies and inflammatory cytokines. Future studies addressing 
the role of B cells in atherogenesis should also investigate the ability of APRIL to 
modulate these responses, being expressed at high levels within the atherosclerotic lesion. 
Future studies should also investigate the ability of APRIL to modulate the phenotype of 
other cells with relevance to atherosclerosis such as macrophages and dendritic cells. Its 
ability to bind and potentially act through heparan sulfate proteoglycans192 is intriguing in 
relevance to its potential role in atherogenesis.  
From a therapeutical point of view, it should be underscored that although most of 
the CAD patients used aspirin as platelet inhibition, they still had raised plasma levels of 
APRIL (paper IV). Moreover, GP IIb/IIIa blocking seems not to influence the release of 
APRIL in activated platelets, and clopidogrel administration does not modify plasma 
levels of APRIL in CAD patients (Sandberg WJ, Otterdal K, and Aukrust P, unpublished 
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data). Based on our in vitro findings, PGE1 and their analogs could potentially inhibit 
platelet-mediated release of APRIL in CAD patients, but the clinical use of these 
compounds for the treatment of cardiovascular diseases is restricted due to unwanted side 
effects.193 If a pathogenic role of APRIL in atherogenesis and plaque destabilization is 
confirmed in forthcoming studies, blocking of APRIL effects or release could be 
investigated as a therapeutic approach in these patients. Blockade of APRIL with TACI-
Ig in a mouse model of systemic lupus erythematosus leads to a significant inhibition of 
disease signs and symptom.194 Based on the large number of literature citations linking 
APRIL/BAFF and their receptors to various diseases, and the resulting interest of at least 
seven biotechnology companies, there is abundant optimism that neutralizing APRIL 
and/or BAFF will prove to be an effective therapy for patients suffering from a variety of 
autoimmune diseases and cancers,183 and potentially also atherosclertic disorders.  
 
7.4 The role of LIGHT in atherosclerotic disorders 
7.4.1 LIGHT - HVEM signaling in atherogenesis 
The TNFSF member LIGHT  have a wide tissue distribution and cell-context specific 
functions due to interaction with two different receptors, the herpes virus entry mediator 
(HVEM) and/or the lymphotoxin  receptor (LTR).195, 196 LIGHT can also bind to a 
soluble receptor, soluble decoy receptor 3 (DcR3), and although it has been shown to 
suppress LIGHT-mediated apoptosis in vitro,197 its biological function is unclear. Both 
LTR and HVEM also have a wide tissue distribution, and in most cases, HVEM-
mediated signaling confer anti-apoptotic or growth-inducing properties, and define 
LIGHT as a co-stimulatory activator of T cells and dendritic cells, whereas LIGHT- 
LTR signaling typically induce apoptosis or cytokine production, or organization of 
lymphoid structures.103, 198-202 LIGHT-HVEM signaling deserve particular focus in 
atherogenesis. First, Lee et al showed strong immunostaining of LIGHT and foam cell-
associated HVEM in atherosclerotic carotid plaques,113 and in paper III we found some 
degree of co-localization of LIGHT and HVEM within the atherosclerotic lesion of apoE-
/- mice, primarily located to the areas of endothelial cells and macrophages. Second, 
HVEM is highly expressed in peripheral lymphocytes, dendritic cells and 
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macrophages,203 and the LIGHT-mediated induction of proatherogenic mediators such as 
TNF-, IL-8 and MMP in monocytes and macrophages could potentially involve HVEM 
signaling pathways. Third, the ability of LIGHT to promote T cell activation in a HVEM 
dependent and CD28 independent manner, preferentially inducing inflammatory Th1 
responses, further support a role for LIGHT-HVEM interaction in atherogenesis.204, 205 
Further, indicative data of vascular LIGHT-HVEM signaling was obtained in mice 
undergoing heart transplantation; injection of HVEM-Ig attenuated progression of vessel 
luminal occlusion, suggesting that the LIGHT-HVEM pathway is involved in the 
development of graft-related vasculopathy.206 Wei et al demonstrated that LIGHT-
HVEM signaling stimulated macrophage migration and promoted vascular SMC 
proliferation, strengthening the hypothesis of a pathogenic LIGHT-HVEM-mediated 
interaction in atherosclerotic disorders.207 Recently, Cai et al showed that CD160, a 
glycosylphosphatidylinositol-anchored member of the immunoglobulin superfamily, 
serves as a negative regulator of CD4+ T cell activation through its interaction with 
HVEM.208 However, at present there are no data on the relative importance of CD160 and 
LIGHT in the HVEM-mediated T cell responses in various clinical disorders including 
atherosclerosis. 
7.4.2 LIGHT and proteinase-activated receptor-2 (PAR-2)   
The interaction between inflammatory mediators and vascular endothelium is an 
important step in atherogenesis and LIGHT has been demonstrated to induce expression 
of inflammatory molecules in endothelial cells. Chang et al showed that LIGHT could 
upregulate ICAM-1 and VCAM-1 expression, leading to increased monocyte adhesion.209 
Also, LIGHT was shown to induce expression of PGI2, GRO- and COX-2, mediated 
through the HVEM receptor, whereas IL-8 was shown to be induced by LIGHT through 
LTR using a LTR-specific LIGHT mutein. 209 We demonstrated additional pro-
inflammatory effects of LIGHT in endothelial cells and macrophages by showing a 
LIGHT-mediated increase of proteinase-activated receptor-2 (PAR-2) expression (paper 
III). In line with its role in inflammatory responses, recent studies suggest a pathogenic 
role of PAR-2 activation in various inflammatory disorders such as arthritis 210, 211 and a 
number of skin disorders.212, 213 In contrast, other studies have provided evidence for a 
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protective, anti-inflammatory role in airways 214-216 and intestine.217, 218 These studies 
indicate that PAR-2 exhibits a duality of function depending at least partly upon the tissue 
and the disease context. In paper III, we demonstrated that LIGHT-HVEM interaction in 
vascular endothelium promoted PAR-2 expression through activation of the c-JUN N-
terminal kinase (JNK) intracellular signaling pathway. LIGHT stimulation of LTR is a 
potent inducer of NFB activation with subsequent induction of a wide range of 
inflammatory responses.  Although we in paper III confirmed NFB activation in 
LIGHT stimulated HUVEC, our blocking experiments strongly suggest that the LIGHT-
mediated induction of PAR-2 in endothelial cells involves the JNK signaling pathway, 
and seems not to be dependent on NFB activation. Although LIGHT-LTR signaling 
recently has been shown to involve JNK activation in fibroblasts.  
219
220 overexpression of 
HVEM seems to be of particular importance for the LIGHT-mediated activation of 
JNK.221  
In paper III, we also showed that LIGHT acted synergistically with PAR-2 
activation to promote an inflammatory response in endothelial cell, suggesting that 
LIGHT-mediated up-regulation of PAR-2 is biological relevant. Thus, whereas the PAR-
2 agonist peptide SLIGKV alone only moderately promoted release of IL-8 and MCP-1 
from endothelial cells in vitro, co-stimulation with LIGHT increased cytokine-release 
more than two-fold compared to LIGHT-stimulation alone, and five- to ten-fold 
compared to PAR-2-stimulation alone. This finding gives support to the notion that 
endothelial-related PAR-2 primarily plays an inflammatory role. In paper II, we showed 
that angina patients had increased plasma levels of LIGHT with particularly high levels 
in those with unstable disease. In paper III we report a same pattern for PAR-2 expression 
in monocytes. We demonstrated the ability of LIGHT to induce PAR-2 expression in 
monocyte-derived macrophages in vitro. Although we have no in vivo data on this issue 
in angina patients, it is tempting to hypothesize that these findings may reflect that an 
inflammatory interaction between LIGHT-PAR-2 also may be operating in vivo in angina 
patients. The demonstration of enhanced expression of PAR-2, LIGHT, and its receptors 
within atherosclerotic lesions of apoE-/- mice, at least partly co-localized in area of 
macrophages and in particular of endothelial cell, further support the in vivo relevance of 
our findings. Although further studies clearly are needed, our findings suggest that 
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LIGHT/PAR-2 driven inflammation, involving HVEM and JNK-mediated signaling, 
could represent a novel pathogenic loop in atherogenesis and plaque progression, 
potentially representing a target for therapy in this disorder. 
7.4.3 LIGHT and lipid metabolism 
LDL and its modified versions, such as oxLDL, play fundamental roles in the 
development of atherosclerosis, as described above. In paper II, we identified LIGHT as a 
possible important mediator of inflammatory response to oxLDL in foam cell 
macrophages, by showing enhanced LIGHT expression in THP-1 macrophages in 
response to oxLDL-stimulation. Moreover, we demonstrated that LIGHT promoted foam 
cell formation at least partly by its ability to up-regulate scavenger receptor-A (SR-A) 
expression in macrophages. Moreover, the LIGHT-mediated enhancement of SR-A 
expression was accompanied by enhanced of acetylated LDL, a modified form of LDL 
that preferentially bind SR-A,222 further supporting the LIGHT-mediated up-regulation of 
SR-A in foam cell formation. Experimental studies have previously established that lipid 
uptake is correlated to the level of SR-A expression in macrophages, 223, 224 and SR-A 
inhibition is shown to reduce atherosclerosis. 223, 225, 226 It is well known that lipids and in 
particular oxLDL may promote inflammatory responses within an atherosclerotic lesion. 
However, inflammatory mediators could also modulate lipid metabolism and our finding 
in paper II suggest that this immune-meditated lipid accumulation could involve LIGHT-
mediated mechanisms. A recent study by Lo et al. further supports such a notion.227 
These authors identified LIGHT as a critical regulator of lipid metabolism by showing 
that over-expression of LIGHT in T cells regulated (i.e., down-regulation of hepatic 
lipase) hepatic gene transcription and induced hypertriglyceridemia and 
hypercholesterolemia through LIGHT-LTR signaling in transgenic mice. They also 
demonstrated that blocking LIGHT-LTR signaling significantly reduced cholesterol 
levels in hypercholesterolemic LDLR-deficient mice. Our findings in paper III, showing 
that LIGHT signaling might interfere with peroxisome-proliferator activator (PPAR)- 
activation further support a link between lipid metabolism and LIGHT.  
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7.4.4 LIGHT and thrombus formation 
While platelet activation and pro-thrombotic stimuli (e.g., PAR-1 activation) may cause 
inflammation, inflammation may also cause thrombus formation. In paper II, we reported 
for the first time potentially pro-thrombotic properties of LIGHT in human macrophages. 
Levels of TF content and macrophages are strongly correlated in the lipid rich areas of 
atherosclerotic lesions, representing an important pro-thrombotic feature of the lesion. 
Previously, TNFSF members such as CD40L and TNF- have been shown to enhance TF 
expression in these cells,116, 228, 229 and in paper II we show that LIGHT could exhibit 
similar properties. Thus, we demonstrated increased TF content in cell lysate from 
LIGHT stimulated THP-1 macrophages, accompanied by increased plasminogen 
activator inhibitor (PAI)-1 expression, indicating that LIGHT promote thrombin 
formation and impair fibrinolytic activities. This was further underscored by a LIGHT-
mediated enhancement thrombin formation as assessed by F1+2 levels in THP-1 
supernatants after adding human plasma to cell cultures. Moreover, the thrombin receptor 
agonist peptide SFLLRN induced LIGHT expression in THP-1 macrophages suggesting a 
possible pathogenic loop promoting thrombus formation, involving interactions with 
LIGHT, thrombin and macrophages.  
Our finding show that LIGHT may transform macrophages into a prothrombotic 
phenotype, and our group has recently shown that a similar mechanism could be operating 
in endothelial cells. Thus, LIGHT stimulation of HUVEC did not only induce the release 
of the prothrombotic and antifibrinolytic mediators TF and PAI-1, respectively, but also 
decreased endothelial production of its natural anticoagulants (i.e., thromomodulin) 
further underscoring the pro-thrombotic potential of LIGHT. Taken together, our findings 
in paper II and III, suggest that LIGHT could serve as a molecular link between lipid 
metabolism, inflammation and thrombus formation, feature that all take place in 
atherosclerotic plaque. 
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8. Conclusions 
The main conclusions presented in this thesis can be extracted as follows: 
 We show enhanced expression of the OPG/RANKL/RANK system both in 
clinical and experimental atherosclerosis, with enhanced T cell expression of 
RANKL as an important feature of unstable disease. Enhanced RANKL 
expression could contribute to atherogenesis and plaque destabilization at least 
partly by promoting chemokine release and matrix degradation. Our observations 
also suggest that OPG under certain circumstances could enhance rather than 
attenuate the MMP-inducing effects of RANKL.   
 Angina patients had markedly increased plasma levels of LIGHT with particularly 
high levels in those with unstable disease. This raised LIGHT level could at least 
partly involve interactions between oxLDL and macrophages. LIGHT was found 
to promote lipid accumulation as well as the expression of TF and PAI-1 in 
macrophages, transforming these cells into a pro-thrombotic and foam cell 
phenotype.  
 The inflammatory interaction between LIGHT and PAR-2 in endothelial cells, 
involving HVEM and JNK signaling pathways, could represent a novel 
pathogenic loop in atherogenesis and plaque progression contributing to vascular 
inflammation within the atherosclerotic lesion.  
 Platelets contain the TNFSF member APRIL, which is released upon platelet 
activation in a gradual manner different from the rapid release of -granule 
content. Although the kinetic may seem similar to that of other platelet-derived 
TNF members, the regulation of APRIL release is different but that of sCD40L 
and LIGHT. APRIL and its corresponding receptors were expressed in thrombus 
material obtained at site of plaque rupture in STEMI patients as well as within 
symptomatic carotid plaques. Our findings suggest that APRIL should be added to 
the list of mediators that are involved in platelet-mediated inflammation during 
atherogenesis. 
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Our findings suggest that the OPG/RANKL/RANK axis as well as LIGHT and APRIL 
could be involved in atherogenesis and plaque destabilization contributing to 
inflammation, thrombus formation, matrix degradation and lipid accumulation. These 
mediators, representing molecular links between different and interacting processes 
during atherogenesis, could potentially represent new targets for therapy in 
atherosclerotic disorders.  
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